

05<sup>th</sup> November, 2022

**BSE Limited** 

P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635 **National Stock Exchange of India Limited** 

Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is to inform you that the US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited's Riverview (Michigan, USA) facility from 31<sup>st</sup> October 2022 to 04<sup>th</sup> November, 2022.

The inspection was completed successfully with Zero Form - 483 observations.

The Company remains committed to maintain the highest standards of compliance.

This is for your information and records.

Thanking you,

Yours truly,

For Piramal Pharma Limited

Vivek Valsaraj Whole-Time Director & CFO